CD33 and neoplasm: Since CD33 and CD123 are not exclusively expressed on AML blasts but also on progenitor and mature hematopoietic cells of the myeloid lineage [11], conventional CD33- and CD123-specific CAR T-cells mediate impressive anti-tumor responses but also bear the risk for long-lasting cytopenias [12,28].